D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-node negative No

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT03833154

Contact name

Kathryn Tower

Clinical trials study type

Oncology - Pulmonary

Clinical trials trial status

Open to Accrual

IRB number

1422369

Principal investigator

Kruti Patel, MD

Clinical trials study number

RTOG3515/D1903C00001

Phone

443-849-3592

Clinical trials title (full)

D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-node negative No